Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | EVP, Chief Operating Officer | November 25, 2023 | November 28, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SANGAMO THERAPEUTICS, INC
Report date November 25, 2023 · Filed November 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 212,471 |
Reported balance
After 2023-11-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-11-25 · Tax withholding · Disposed 1,925 · Balance 212,471 F1: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on November 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2023 of $0.3821/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2: Includes: (a) 3,644 shares resulting from the November 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 27,844 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 13,336 shares subject to Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 56,250 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on November 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2023 of $0.3821/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
F2: Includes: (a) 3,644 shares resulting from the November 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 27,844 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 13,336 shares subject to Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 56,250 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 25, 2023 Filed Nov 28, 2023 21:19 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,925 | $0.38 | $735.54 |
DisclosureSEC source: 0001209191-23-056788 · doc4.xml · nonDerivative · entry 1 McClung David Mark · CIK 0001811505 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,471 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on November 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2023 of $0.3821/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 3,644 shares resulting from the November 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 27,844 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 13,336 shares subject to Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 56,250 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 20:15 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,925 | $0.77 | $1,482.25 |
DisclosureSEC source: 0001209191-23-047586 · doc4.xml · nonDerivative · entry 1 McClung David Mark · CIK 0001811505 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,396 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on August 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 25, 2023 of $0.77/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 3,644 shares resulting from the August 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 33,413 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 13,336 shares subject to Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (d) 56,250 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F3 · balance_after: Includes 5,000 shares acquired on May 31, 2023 under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| June 25, 2023 Filed Jun 26, 2023 20:31 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 11,528 | $1.19 | $13,718.32 |
DisclosureSEC source: 0001209191-23-039711 · doc4.xml · nonDerivative · entry 1 McClung David Mark · CIK 0001811505 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,321 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on June 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on June 25, 2023 of $1.19/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 21,812 shares resulting from the June 25, 2023 final vesting installment of the Reporting Person's June 25, 2020 RSU grant, (b) 38,982 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, (c) 13,336 shares subject to Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (d) 56,250 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| May 25, 2023 Filed May 30, 2023 20:43 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,925 | $1.33 | $2,560.25 |
DisclosureSEC source: 0001209191-23-032910 · doc4.xml · nonDerivative · entry 1 McClung David Mark · CIK 0001811505 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,849 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on May 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2023 of $1.33/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 3,643 shares resulting from the May 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 38,982 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 33,340 shares subject to the Reporting Person's June 25, 2020 RSU grant that will vest in one final installment on June 25, 2023, (c) 13,336 shares subject to Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (d) 56,250 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2023 Filed Mar 6, 2023 22:09 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 9,745 | $2.66 | $25,921.70 |
DisclosureSEC source: 0001209191-23-016395 · doc4.xml · nonDerivative · entry 2 McClung David Mark · CIK 0001811505 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,774 F3 · shares: Represents shares underlying the portions of RSU grants that vested on February 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2023 of $2.66/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes 2,453 shares acquired on November 30, 2022 under the Issuer's 2020 Employee Stock Purchase Plan. F4 · balance_after: Includes: (a) 8,722 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2021 RSU grant and 13,336 shares subject to such RSU grant that will vest in one final installment on February 25, 2024, (b) 9,715 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 44,550 shares will vest in 8 successive equal quarterly installments thereafter and (c) 33,430 shares subject to the Reporting Person's June 25, 2020 RSU grant that will vest in one final installment on June 25, 2023. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 24, 2023 Filed Mar 6, 2023 22:09 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 262,500 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001209191-23-016395 · doc4.xml · derivative · entry 3 McClung David Mark · CIK 0001811505 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,500 Underlying: Common Stock · 262,500 shares Expires 2033-02-23 F5 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 24, 2023 Filed Mar 6, 2023 22:09 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 56,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016395 · doc4.xml · nonDerivative · entry 1 McClung David Mark · CIK 0001811505 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,519 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration as provided in the 2018 EIP. F2 · balance_after: Includes 2,453 shares acquired on November 30, 2022 under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| June 25, 2022 Filed Jun 28, 2022 21:25 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 11,525 | $4.31 | $49,672.75 |
DisclosureSEC source: 0001209191-22-039649 · doc4.xml · nonDerivative · entry 1 McClung David Mark · CIK 0001811505 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,816 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on June 25, 2022 which were surrendered by the Reporting Person to the Issuer solely for mandatory tax withholding purposes using the Issuer's closing stock price on June 24, 2022 of $4.31/share pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 21,805 shares resulting from the June 25, 2022 vesting of the Reporting Person's June 25, 2020 RSU grant and 33,340 shares subject to such RSU grant that will vest in one final annual installment on June 25, 2023, (b) 26,668 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in two remaining annual installments of 13,332 shares and 13,336 shares on February 25, 2023 and 2024, respectively, and (c) 59,400 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F3 · balance_after: Includes 2,357 shares acquired on May 31, 2022 under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:17 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 160,380 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0001209191-22-014167 · doc4.xml · derivative · entry 3 McClung David Mark · CIK 0001811505 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,380 Underlying: Common Stock · 160,380 shares Expires 2032-02-24 F5 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:17 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 59,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014167 · doc4.xml · nonDerivative · entry 2 McClung David Mark · CIK 0001811505 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,984 F4 · shares: Represents shares of common stock issuable upon settlement of an RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:17 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 4,610 | $5.90 | $27,199.00 |
DisclosureSEC source: 0001209191-22-014167 · doc4.xml · nonDerivative · entry 1 McClung David Mark · CIK 0001811505 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,584 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on February 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on February 25, 2022 of $5.90/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). F2 · balance_after: Includes: (a) 8,722 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2021 RSU grant and 26,668 shares subject to such RSU grant that will vest in two remaining annual installments of 13,332 shares and 13,336 shares on February 25, 2023 and 2024, respectively, and (b) 66,670 shares subject to the Reporting Person's June 25, 2020 RSU grant that will vest in two remaining annual installments of 33,330 shares and 33,340 shares on June 25, 2022 and 2023, respectively. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F3 · balance_after: Includes 900 shares acquired on November 30, 2021 under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 23:55 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 11,525 | $12.02 | $138,530.50 |
DisclosureSEC source: 0001209191-21-043811 · doc4.xml · nonDerivative · entry 1 McClung David Mark · CIK 0001811505 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,294 F1 · shares: Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on June 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on June 25, 2021 of $12.02/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"). F2 · balance_after: Includes: (a) 21,805 shares resulting from the June 25, 2021 vesting of the Reporting Person's June 25, 2020 RSU grant and 66,670 shares subject to such RSU grant that will vest in two remaining annual installments on June 25, 2022 and June 25, 2023; (b) 40,000 shares subject to a grant of RSUs to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended; and (3) 819 shares acquired by the Reporting Person on May 28, 2021 under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:10 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $11.19 | $0.00 |
DisclosureSEC source: 0001209191-21-015520 · doc4.xml · derivative · entry 2 McClung David Mark · CIK 0001811505 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-02-24 F3 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person measured from the February 25, 2021 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through each such vesting date, and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:10 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015520 · doc4.xml · nonDerivative · entry 1 McClung David Mark · CIK 0001811505 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 F1 · shares: Represents 40,000 shares of common stock issuable upon settlement of restricted stock units ("RSUs"), granted to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")) through such dates. F2 · balance_after: Includes 100,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on June 25, 2020. The RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended through such dates. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 01:11 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $9.16 | $0.00 |
DisclosureSEC source: 0001209191-20-039346 · doc4.xml · derivative · entry 2 McClung David Mark · CIK 0001811505 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-06-24 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person measured from the June 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through each such vesting date, and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 01:11 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-039346 · doc4.xml · nonDerivative · entry 1 McClung David Mark · CIK 0001811505 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F1 · shares: Includes 100,000 shares of common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person on June 25, 2020. The RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.